Vomit-free days up to day 10. by Bruno Martins Tomazini (6509528)

“…<div><p>Background</p><p>Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent <i>in vitro</i> activity against SARS-CoV-2 virus. …”

Symptoms free-days up to day 10. by Bruno Martins Tomazini (6509528)

“…<div><p>Background</p><p>Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent <i>in vitro</i> activity against SARS-CoV-2 virus. …”

Respiratory symptoms-free days up to day 10. by Bruno Martins Tomazini (6509528)

“…<div><p>Background</p><p>Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent <i>in vitro</i> activity against SARS-CoV-2 virus. …”

Other symptoms-free days up to day 10. by Bruno Martins Tomazini (6509528)

“…<div><p>Background</p><p>Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent <i>in vitro</i> activity against SARS-CoV-2 virus. …”

Diarrhea-free days up to day 10. by Bruno Martins Tomazini (6509528)

“…<div><p>Background</p><p>Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent <i>in vitro</i> activity against SARS-CoV-2 virus. …”

Gastrointestinal symptoms-free days up to day 10. by Bruno Martins Tomazini (6509528)

“…<div><p>Background</p><p>Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent <i>in vitro</i> activity against SARS-CoV-2 virus. …”

Nausea-free days up to day 10. by Bruno Martins Tomazini (6509528)

“…<div><p>Background</p><p>Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent <i>in vitro</i> activity against SARS-CoV-2 virus. …”

Flow of patients in Halos trial. by Bruno Martins Tomazini (6509528)

“…<div><p>Background</p><p>Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent <i>in vitro</i> activity against SARS-CoV-2 virus. …”

Cough-free days up to day 10. by Bruno Martins Tomazini (6509528)

“…<div><p>Background</p><p>Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent <i>in vitro</i> activity against SARS-CoV-2 virus. …”

Dyspnea-free days up to day 10. by Bruno Martins Tomazini (6509528)

“…<div><p>Background</p><p>Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent <i>in vitro</i> activity against SARS-CoV-2 virus. …”

Raincloud plots with median, quartile, density and individual data points for CV%’s of the DJ metrics across the three time-points analyzed. by Nicolas M. Philipp (13272198)

Biological processes showing up-regulation or down-regulation of genes in activated neutrophils. by Jeffrey A. Ericson (639257)

“…<p>(<b>A–H</b>). Heat maps show mean expression in neutrophils from blood (BL), synovial fluid (SF), or peritonitis induced by uric acid (UA) or thioglycollate (TG). …”

Thymol and its combination with classical anthelmintics. by Guillermina Hernando (553795)

<i>NAB3</i> reduces the level of <i>IMD2</i> CUT terminator readthrough product from a reporter and native <i>IMD2</i> CUT and readthrough RNA, but <i>NAB3</i> does not significant... by Milo B. Fasken (659389)

“…<i>nab3-R331A</i>, <i>nab3-F333A</i>, and <i>nab3-S399A</i> RRM mutants do not decrease level of GFP from pREF-GFP reporter in <i>air1/2</i> cells. …”

Pre-incubation of SB105-A10 either with HIV-1_IIIb or HIV-1_ada strains inhibits the viral infectivity in dilution assay. by Isabella Bon (467395)

“…<p>HIV-1 strains were incubated for 1 hour at 37°C with SB105-A10 (20 µg/ml; 4.2 µM). Following this incubation the samples were diluted 50-fold to reduce dendrimer concentrations to a level below that at which SB105-A10 significantly inhibits HIV replication and challenged with activated PBMCs. …”

Influences of parabolic flight on activity of wrist and trunk activities. by Peiliang Wang (753153)

Cumulative and ruptured oocysts. by Lauren M. Childs (593877)

Effects of DMSO on chromosome alignment and spindle organization of <i>in vitro</i> matured porcine oocytes. by Xuan Li (137217)

Comparison of life cycle model with published data. by Lauren M. Childs (593877)

Reaction Mechanism Underlying Pd(II)-Catalyzed Oxidative Coupling of Ethylene and Benzene to Form Styrene: Identification of a Cyclic Mono-Pd^II Bis-Cu^II Compl... by Charles B. Musgrave (3071073)

“…The PdCu₂(μ-OAc)₆ cyclic trimer leads to a CMD barrier of 33.5 kcal/mol, while the [Pd­(μ-OAc)₂]₃ species leads to a larger CMD barrier at >35 kcal/mol. …”